Volume-11 , Issue-1 , Mar 2024, ISSN 2349-3178 (Print), 2349-3186 (Online)

• Open Access   Article

  Semaglutide and Obesity: Real-World Clinical Applications and Outcomes

  Swati Sucharita Dash, Merlin Roshma Sherin, Debalina Das, Guruprasad KS Rao

  Research Paper | Journal-Paper (IJMSRP)

  Vol.11 , Issue.1 , pp.1-14, Mar-2024

  Abstract

  Full-Text HTML

  References

  Citation

  Abstract
  Obesity, a chronic and complex disease, is projected to have a prevalence of 49% by 2030 and is linked to various comorbidities, including type 2 diabetes, hypertension, dyslipidemia, stroke, coronary heart disease, and cancers, resulting in a substantial economic burden. Effective weight management is crucial to reduce morbidity and mortality. Semaglutide, initially developed as a GLP-1 receptor agonist for treating type 2 diabetes, is now being explored for its potential in addressing obesity. Its utilization is expanding to chronic weight management as it mimics the effects of GLP-1, regulating blood sugar levels and appetite. The FDA approved the use of a 2.4 mg injection of semaglutide once weekly for chronic weight management. Semaglutide proves efficacy for weight loss in obesity, endorsed by STEP trial findings and real-world data, with safety akin to GLP-1RA class, promoting long-term adherence. Its notable effects on albuminuria, HbA1c, heart failure, and quality of life herald a transformative paradigm in obesity and associated comorbidity management. Through a review of existing literature and clinical studies, this article provides a nuanced overview of the diverse real-world scenarios where semaglutide has been applied, elucidating its impact on weight management and associated health outcomes.

  Key-Words / Index Term
  Obesity, Weight loss, Semaglutide, Real-world, GLP-1RA

  References
  [1] World Health Organization, “Obesity and overweight,” World Health Organization, Mar. 01, 2024.
  [2] “Obesity causes and treatments,” www.nhsinform.scot, Nov. 21, 2023.
  [3] S. Abdi Beshir et al., “A narrative review of approved and emerging anti-obesity medications,” Saudi Pharmaceutical Journal, vol. 31, no. 10, 101757, Oct. 2023, doi: https://doi.org/10.1016/j.jsps.2023.101757.
  [4] A. Ruban, K. Stoenchev, H. Ashrafian, and J. Teare, “Current treatments for obesity,” Clinical Medicine, vol. 19, no. 3, pp. 205–212, May 2019, doi: https://doi.org/10.7861/clinmedicine.19-3-205.
  [5] P. Marzullo et al., “Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients,” Journal of Endocrinological Investigation, vol. 45, no. 8, pp. 1587–1598, Apr. 2022, doi: https://doi.org/10.1007/s40618-022-01799-2.
  [6] W. Ghusn et al., “Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity,” JAMA Network Open, vol. 5, no. 9, p. e2231982, Sep. 2022, doi: https://doi.org/10.1001/jamanetworkopen.2022.31982.
  [7] J. Xiang et al., “Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.,” PubMed, vol. 27, no. 20, pp. 9908–9915, Oct. 2023, doi: https://doi.org/10.26355/eurrev_202310_34169.
  [8] D. H. Ryan and S. R. Yockey, “Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over,” Current Obesity Reports, vol. 6, no. 2, pp. 187–194, Apr. 2017, doi: https://doi.org/10.1007/s13679-017-0262-y.
  [9] K. Alabduljabbar, M. Alsaqaaby, K. J. Neff, M. Crotty, and C. W. le Roux, “Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting,” Endocrine, vol. 83, no. 2, pp. 392–398, Sep. 2023, doi: https://doi.org/10.1007/s12020-023-03534-0.
  [10] M. Menzen, T. L. Berentzen, A.-M. Catarig, S. Pieperhoff, J. Simon, and S. Jacob, “Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany,” Experimental and Clinical Endocrinology & Diabetes, vol. 131, no. 4, pp. 205–215, Jan. 2023, doi: https://doi.org/10.1055/a-2007-2061.
  [11] W. C. Powell et al., “Medications and conditions associated with weight loss in patients prescribed semaglutide based on real?world data,” Obesity, vol. 31, no. 10, pp. 2482–2492, Aug. 2023, doi: https://doi.org/10.1002/oby.23859.
  [12] J. Bonnet et al., “Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery,” Obesity, vol. 32, no. 1, pp. 50–58, Nov. 2023, doi: https://doi.org/10.1002/oby.23922.
  [13] Natia Murvelashvili et al., “Effectiveness of semaglutide versus liraglutide for treating post?metabolic and bariatric surgery weight recurrence,” Obesity, vol. 31, no. 5, pp. 1280–1289, Mar. 2023, doi: https://doi.org/10.1002/oby.23736.
  [14] A. B. Jensen et al., “Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric Surgery: a Retrospective Observational Study,” Obesity Surgery, vol. 33, no. 4, pp. 1017–1025, Feb. 2023, doi: https://doi.org/10.1007/s11695-023-06484-8.
  [15] A. Lautenbach et al., “The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis,” Obesity Surgery, vol. 32, no. 10, pp. 3280–3288, Jul. 2022, doi: https://doi.org/10.1007/s11695-022-06211-9.
  [16] S. Roy Chaudhuri, A. Majumder, P. Mukherjee, D. Sanyal, S. Chakraborty, and S. Chuyan, “Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India,” Cureus, vol. 15, no. 6, p. e40179, Jun. 2023, doi: https://doi.org/10.7759/cureus.40179.
  [17] J. Seijas-Amigo et al., “Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase,” Primary Care Diabetes, vol. 17, no. 4, pp. 366–372, May 2023, doi: https://doi.org/10.1016/j.pcd.2023.05.004.
  [18] C. Di Loreto, V. Minarelli, G. Nasini, R. Norgiolini, and P. Del Sindaco, “Correction to: Effectiveness in Real World of Once-Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria,” Diabetes Therapy, vol. 13, no. 6, p. 1251, Apr. 2022, doi: https://doi.org/10.1007/s13300-022-01263-7.
  [19] A. Okamoto, H. Yokokawa, T. Nagamine, H. Fukuda, T. Hisaoka, and T. Naito, “Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists,” Journal of Diabetes & Metabolic Disorders, vol. 20, no. 2, pp. 2121–2128, Sep. 2021, doi: https://doi.org/10.1007/s40200-021-00899-9.
  [20] B. Aviles Bueno, M. J. Soler, L. Perez-Belmonte, A. Jimenez Millan, F. Rivas Ruiz, and M. D. Garcia de Lucas, “Semaglutide in type 2 diabetes with chronic kidney disease at high-risk progression—real-world clinical practice,” Clinical Kidney Journal, vol. 15, no. 8, pp. 1593–1600, Apr. 2022, doi: https://doi.org/10.1093/ckj/sfac096.
  [21] L. M. Pérez-Belmonte et al., “Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice,” Frontiers in Endocrinology, vol. 13, p. 851035, 2022, doi: https://doi.org/10.3389/fendo.2022.851035.
  [22] S. Ali et al., “Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients,” Diabetes, Obesity & Metabolism, vol. 26, no. 3, pp. 989–996, Dec. 2023, doi: https://doi.org/10.1111/dom.15398.
  [23] S. O. Oguche, M. S. Maleshesh, D. Ishaq, "The Role of Epigenetics in the Development of Human Obesity and Type 2 Diabetes: A Review," International Journal of Medical Science Research and Practice, Vol.10, Issue.3, pp.6-15, 2023.
  [24] T. Parvin, T. Nasrin, J. Khatun, M. Chatterjee, "Predictive Machine Learning Model for Detection and Classification of Diabetes", International Journal of Scientific Research in Multidisciplinary Studies , Vol.7, Issue.9, pp.11-17, 2021.
  [25] H. Gasoyan, M. A. Fiala, M. Doering, R. Vij, M. Halpern, and G. A. Colditz, “Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review,” Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 11, pp. e420–e427, Nov. 2023, doi: https://doi.org/10.1016/j.clml.2023.08.008.

  Citation
  Swati Sucharita Dash, Merlin Roshma Sherin, Debalina Das, Guruprasad KS Rao, "Semaglutide and Obesity: Real-World Clinical Applications and Outcomes," International Journal of Medical Science Research and Practice, Vol.11, Issue.1, pp.1-14, 2024